FDA Approved: AMPYRA — Supplemental Application (Merz Pharmaceuticals, LLC)

View source ↗

Summary

The FDA approved a supplemental application for AMPYRA (dalfampridine) submitted by Merz Pharmaceuticals, LLC. This action updates the existing NDA022250.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ampyra (4-aminopyridine)

Snippet

SUPPL AP for AMPYRA (DALFAMPRIDINE)